Please try another search
For the six months ended 30 June 2021, Palla Pharma Ltd revenues decreased 43% to A$7.1M. Net loss increased from A$9M to A$33.1M. Revenues reflect Norway segment decrease of 37% to A$6.2M, Australia segment decrease of 66% to A$863K, Norway segment decrease of 37% to A$6.2M, Australia segment decrease of 66% to A$863K. Higher net loss reflects Labor & Related Expenses in SGA increase of 19% to A$5.8M (expense).
Period Ending: | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 7.06 | 9.78 | 12.33 | 27.49 |
Gross Profit | -3.5 | -2.85 | 1.79 | 7.95 |
Operating Income | -32.17 | -24.7 | -8.02 | -2.08 |
Net Income | -33.11 | -25.74 | -9.01 | -3.56 |
Period Ending: | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 49.89 | 67.42 | 86.17 | 89.57 |
Total Liabilities | 29.82 | 31.3 | 24.43 | 18.16 |
Total Equity | 20.07 | 36.12 | 61.74 | 71.41 |
Period Ending: | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -13.35 | -14.78 | -5.44 | -9.47 |
Cash From Investing Activities | -0.38 | 0.77 | -2.15 | -2.48 |
Cash From Financing Activities | 13.93 | 12.53 | 7.37 | 11.69 |
Net Change in Cash | 0.29 | -1.41 | -0.37 | 0.11 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review